Nodular thyroid disease medical therapy

Jump to navigation Jump to search

Nodular thyroid disease Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Nodular thyroid disease from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Ultrasound

Fine Needle Aspiration

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Nodular thyroid disease medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Nodular thyroid disease medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Nodular thyroid disease medical therapy

CDC on Nodular thyroid disease medical therapy

Nodular thyroid disease medical therapy in the news

Blogs on Nodular thyroid disease medical therapy

Directions to Hospitals Treating Nodular thyroid disease

Risk calculators and risk factors for Nodular thyroid disease medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

  • Radioiodine (I-131) is as effective as surgery for the treatment of toxic multinodular goiter, however has a more prolonged reversal of hyperthyroidism after therapy. It has also been used for the treatment of non-toxic multinodular goiter.
  • Antithyroid drugs, such as propylthiouracil (PTU) or methimazole are not 1st line agents in treating nodular thyroid disease when overt hyperthyroidism is present. This is primarily due to the fact that this treatment would be lifelong. These drugs are mainly used prior to surgery, as they have been shown to lower the operative risk. Additionally, when given prior to radioiodine therapy, they have been shown to achieve a state of euthyroidism more rapidly, and decrease the exacerbations of hyperthyroidism.
    • Recent studies, however, report no significant difference between thyroxine and placebo for the treatment of benign nodules.
    • If a nodule grows, with or without replacement, surgery is indicated.

References


Template:WikiDoc Sources